Cutaneous sarcoidosis is a skin condition that appears in up to one third of people with sarcoidosis, a complex disease involving multiple body systems. Managing these skin changes requires understanding treatment options that range from topical creams to medications affecting the entire body, along with newer approaches being studied in clinical research.

Understanding Treatment Goals for Skin Involvement in Sarcoidosis

When sarcoidosis affects the skin, treatment focuses on reducing inflammation, improving the appearance of skin lesions, and preventing long-term complications. The goal is not necessarily to cure the condition, since sarcoidosis may resolve on its own in some cases, but rather to control symptoms and improve quality of life. Treatment choices depend heavily on how severe the skin involvement is, which parts of the body are affected, and whether the disease is limited to the skin or involves other organs like the lungs, heart, or eyes.^[1]

The intensity of treatment varies considerably from person to person. Someone with just a few small papules on the face might need only a topical cream, while another person with widespread plaques or the more persistent form called lupus pernio may require oral medications that affect the immune system throughout the body. Doctors also consider whether the sarcoidosis is actively causing problems or whether it might be better to watch and wait, since the disease can sometimes improve without intervention.^[8]

Standard treatments for cutaneous sarcoidosis have been used for decades and are recommended by medical societies based on years of clinical experience. At the same time, researchers continue exploring new therapies in clinical trials, testing drugs that target specific parts of the immune system or inflammation process. These investigational treatments offer hope for patients who don’t respond well to conventional options or who experience troubling side effects.^[9]

Standard Treatments for Cutaneous Sarcoidosis

The most widely accepted approach to treating cutaneous sarcoidosis follows a stepwise pattern, starting with the least aggressive options and progressing to more powerful medications if needed. This strategy helps minimize side effects while still providing effective symptom control.^[9]

Topical Corticosteroids

For localized skin lesions, potent topical corticosteroids—medications that reduce inflammation—are often the first choice. Examples include clobetasol, a very strong steroid cream or ointment applied directly to affected skin. These medications work by suppressing the immune system’s activity in the skin, which reduces the formation of the tiny inflammatory clusters called granulomas that characterize sarcoidosis.^[9]

Topical steroids are convenient because they act locally where applied, minimizing effects on the rest of the body. However, they work best for papules and small plaques. Thicker lesions or widespread involvement may not respond adequately to topical treatment alone. Long-term use of potent topical steroids can cause skin thinning, stretch marks, or changes in skin color, so doctors monitor patients regularly and may rotate treatment areas or adjust the strength of the medication.^[1]

Intralesional Corticosteroid Injections

When skin lesions are too thick or resistant to respond to creams, doctors may inject corticosteroids directly into the affected areas. Triamcinolone is the most commonly used medication for these injections, typically given at doses ranging from 3 to 10 milligrams per injection site. The medication is delivered directly into the lesion using a small needle, allowing higher concentrations of the drug to reach the problem area without exposing the entire body to systemic effects.^[9]

This approach can be quite effective for individual plaques or nodules, but it requires repeated visits to the clinic and can be uncomfortable. Some patients experience temporary pain, minor bleeding, or slight depression of the skin at injection sites. The treatment may need to be repeated every few weeks or months depending on response.^[1]

Antimalarial Medications

Despite their name, antimalarial drugs like hydroxychloroquine and chloroquine have proven useful in treating cutaneous sarcoidosis, even though they were originally developed to fight malaria parasites. These medications appear to work by modulating the immune system and reducing inflammation through mechanisms that aren’t completely understood. They have become a cornerstone of treatment for cutaneous sarcoidosis, particularly for chronic or widespread skin involvement.^[9]

Antimalarials are taken orally, usually once or twice daily. They can take several months to show full benefit, so patience is required. Common side effects include stomach upset, nausea, and occasionally skin rashes. A more serious but rare concern is damage to the retina of the eye, which can affect vision. Because of this risk, patients taking these medications need regular eye examinations, typically every 6 to 12 months, to detect any early changes before permanent damage occurs.^[9]

Methotrexate

When topical treatments and antimalarials aren’t sufficient, doctors often turn to methotrexate, a medication that suppresses the immune system more broadly. Methotrexate was originally developed as a cancer treatment but is now widely used for inflammatory conditions at much lower doses. For cutaneous sarcoidosis, it helps reduce the formation of granulomas and calms the overactive immune response driving skin inflammation.^[9]

Methotrexate is typically taken once weekly as a pill or sometimes as an injection. The starting dose is usually low and gradually increased until the desired effect is achieved or side effects become limiting. Because methotrexate affects rapidly dividing cells, it can cause mouth sores, nausea, fatigue, and hair thinning. More seriously, it can affect liver function and blood cell production, so regular blood tests are necessary to monitor for these complications. Patients taking methotrexate also need to take folic acid supplements to reduce side effects. Women of childbearing age must use reliable contraception because methotrexate can cause severe birth defects.^[9]

Systemic Corticosteroids

For patients with severe, disfiguring, or rapidly progressive cutaneous sarcoidosis, systemic corticosteroids like prednisone remain the most effective treatment option. These medications are taken by mouth and affect the entire body, powerfully suppressing inflammation and immune system activity. Systemic steroids can produce dramatic improvement in skin lesions, often within weeks.^[1]

However, the benefits come with significant trade-offs. Long-term use of oral corticosteroids causes a wide range of side effects including weight gain, increased blood sugar levels (which can lead to diabetes), high blood pressure, bone weakening (osteoporosis), mood changes, increased risk of infections, and thinning of the skin. Because of these concerns, doctors try to use the lowest effective dose for the shortest time possible. Often, steroids are started at a higher dose to get the disease under control, then slowly tapered down while other medications like methotrexate or antimalarials are added to maintain improvement.^[9]

The duration of treatment with any of these medications varies widely. Some patients need only a few months of therapy if their sarcoidosis goes into remission—a period when symptoms disappear or greatly diminish. Others require ongoing treatment for years to keep the disease under control. Doctors carefully monitor patients for both disease activity and medication side effects, adjusting treatment as needed.^[13]

Emerging Treatments in Clinical Trials

While standard treatments help many patients with cutaneous sarcoidosis, they don’t work for everyone, and some people can’t tolerate the side effects. This has motivated researchers to test newer medications that target specific parts of the immune system with greater precision. These investigational therapies are being studied in clinical trials around the world, including in the United States, Europe, and other regions.^[6]

Biological Therapies and TNF Inhibitors

One of the most promising areas of research involves medications called biological agents or biologics. These are complex proteins produced through biotechnology that target specific molecules involved in inflammation. Among the most studied for sarcoidosis are drugs that block tumor necrosis factor alpha (TNF-α), a chemical messenger that plays a key role in the inflammatory process.^[8]

Several TNF inhibitors originally developed for other inflammatory conditions like rheumatoid arthritis and psoriasis are being tested in sarcoidosis patients. These medications work by binding to TNF-α and preventing it from attaching to receptors on cells, thereby blocking the cascade of inflammation that leads to granuloma formation. Because they target a specific part of the immune system rather than suppressing it broadly, they may cause fewer side effects than traditional immunosuppressants.^[8]

Clinical trials of TNF inhibitors for cutaneous sarcoidosis are typically conducted in phases. Phase I trials focus primarily on safety, testing the medication in a small number of healthy volunteers or patients to determine appropriate doses and identify common side effects. Phase II trials enroll more patients to assess whether the drug actually improves symptoms and to continue monitoring safety. Phase III trials involve larger groups of patients and compare the new treatment against current standard therapies or placebo to determine if it offers real advantages.^[6]

Early results from some clinical trials have shown that TNF inhibitors can improve skin lesions in patients with cutaneous sarcoidosis who haven’t responded well to conventional treatments. Some patients have experienced significant reduction in the size and redness of plaques, improvement in lupus pernio, and better overall quality of life. However, these medications are given by injection or intravenous infusion rather than as pills, require regular administration (often every few weeks), and come with their own set of potential side effects including increased risk of serious infections, allergic reactions, and rarely, paradoxical worsening of sarcoidosis or development of other autoimmune conditions.^[8]

Other Immunomodulatory Agents

Beyond TNF inhibitors, researchers are investigating other medications that modify immune system function through different mechanisms. Some clinical trials are testing drugs that target other inflammatory molecules like interleukins—chemical messengers that help regulate immune responses. By blocking specific interleukins involved in granuloma formation, these medications aim to reduce inflammation more selectively.^[8]

The advantage of targeting specific molecules is the potential for effective treatment with fewer broad side effects. For example, drugs that block interleukin-23 or interleukin-17, which play roles in certain inflammatory pathways, are being studied in sarcoidosis after showing success in other granulomatous and inflammatory skin conditions. These agents work by interrupting the signaling that recruits inflammatory cells to affected tissues and promotes granuloma persistence.^[8]

Clinical trials testing these newer biological agents typically involve careful patient selection. Researchers often enroll patients with moderate to severe cutaneous sarcoidosis who have failed at least one or two standard treatments. Trial participants undergo regular monitoring with skin examinations, blood tests to assess safety and organ function, and sometimes skin biopsies to evaluate how the medication is affecting the microscopic appearance of lesions.^[6]

Novel Small Molecule Drugs

Another research direction involves small molecule drugs that can be taken orally and work by interfering with specific enzymes or proteins inside cells. These medications are designed to be more convenient than injectable biologics while still offering targeted immune modulation. Some of these drugs have code names or experimental designations during early testing before they receive official names if approved.^[6]

The mechanism of action varies depending on the specific drug. Some work by inhibiting enzymes called JAK kinases that transmit inflammatory signals inside cells. By blocking these enzymes, the drugs interrupt multiple inflammatory pathways simultaneously. Others target different cellular machinery involved in immune cell activation or movement to sites of inflammation.^[6]

Preliminary results from some Phase II trials have shown that certain small molecule inhibitors can reduce inflammatory markers in the blood and improve skin lesions in sarcoidosis patients. The oral route of administration makes these drugs more convenient than injections, potentially improving patient adherence to treatment. However, because they affect intracellular signaling pathways used by many cell types, these medications can have side effects including increased infection risk, changes in blood counts, and effects on cholesterol and liver function.^[6]

Location and Eligibility for Clinical Trials

Clinical trials for cutaneous sarcoidosis are conducted at academic medical centers and specialized research sites. In the United States, many trials take place at universities and teaching hospitals with expertise in sarcoidosis. European countries, particularly those with higher incidence of sarcoidosis like Scandinavian nations, also conduct significant research. Participation in some international trials may be possible depending on the study design.^[6]

Eligibility for clinical trials depends on many factors. Typically, researchers look for patients with confirmed diagnosis of cutaneous sarcoidosis based on skin biopsy showing noncaseating granulomas, with active skin lesions of a certain severity. Many trials require that patients have tried and not adequately responded to at least one standard treatment. Other considerations include age, overall health status, what other organs are affected by sarcoidosis, and what medications the person is currently taking.^[6]

Patients interested in clinical trials can ask their dermatologist or sarcoidosis specialist about ongoing studies, search clinical trial registries online, or contact sarcoidosis patient organizations that maintain lists of active research studies. Trial participation usually involves more frequent clinic visits and monitoring than standard care, but the treatment and tests are typically provided at no cost to participants.^[6]

Most common treatment methods

• Topical Corticosteroids
  • Potent steroid creams or ointments like clobetasol applied directly to skin lesions
  • Work by reducing inflammation locally in the skin
  • Most effective for papules and small plaques
  • May cause skin thinning with long-term use
• Intralesional Corticosteroid Injections
  • Triamcinolone injected directly into individual lesions
  • Doses typically range from 3 to 10 milligrams per injection site
  • Useful for thick plaques resistant to topical treatment
  • Requires repeated clinic visits for administration
• Antimalarial Medications
  • Hydroxychloroquine and chloroquine taken orally
  • Modulate immune system function and reduce inflammation
  • May take several months to show full benefit
  • Require regular eye examinations to monitor for retinal toxicity
• Methotrexate
  • Immunosuppressive medication taken once weekly
  • Reduces granuloma formation and immune system activity
  • Requires regular blood tests to monitor liver function and blood counts
  • Patients must take folic acid supplements to reduce side effects
• Systemic Corticosteroids
  • Oral prednisone for severe or widespread cutaneous involvement
  • Most effective treatment for rapidly reducing inflammation
  • Multiple potential side effects with long-term use
  • Usually started at higher doses then gradually tapered
• Biological Therapies
  • TNF inhibitors that block tumor necrosis factor alpha
  • Given by injection or intravenous infusion
  • Being tested in clinical trials for refractory cases
  • Target specific inflammatory pathways with potential for fewer broad side effects